Author

Abdulafeez Oluyadi

Observed names: A Oluyadi, A. Oluyadi

Institution: Agios Pharmaceuticals (United States)

Observed institutions: Agios Pharmaceuticals (United States), Karyopharm Therapeutics (United States)

OpenAlex ID: A5040041297

Mitapivat in adult patients with pyruvate kinase deficiency receiving regular transfusions (ACTIVATE-T): a multicentre, open-label, single-arm, phase 3 trial

2022 · Andreas Glenthøj, Eduard J van Beers, et al. · The Lancet Haematology · 52

Safety and efficacy of mitapivat in sickle cell disease (RISE UP): results from the phase 2 portion of a global, double-blind, randomised, placebo-controlled trial

2024 · Modupe Idowu, Lucas Otieno, et al. · The Lancet Haematology · 34

Ivosidenib (AG-120) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome: Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

2019 · James M. Foran, Courtney D. DiNardo, et al. · Blood · 20

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study of Mitapivat in Patients with Sickle Cell Disease: RISE UP Phase 2 Results

2023 · Modupe Idowu, Lucas Otieno, et al. · Blood · 5

MDS-265: Ivosidenib (IVO) in Patients with IDH1-Mutant Relapsed/Refractory Myelodysplastic Syndrome (R/R MDS): Updated Enrollment of a Phase 1 Dose Escalation and Expansion Study

2020 · Courtney D DiNardo, James M Foran, et al. · Clinical Lymphoma Myeloma & Leukemia · 5

A Phase 2b Study of Selinexor in Patients With Relapsed/refractory (r/r) Diffuse Large B‐cell Lymphoma (dlbcl)

2019 · N. Kalakonda, F. Cavallo, et al. · Hematological Oncology · 5

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled Study of Mitapivat in Patients with Sickle Cell Disease

2021 · Joanna Howard, Kevin H.M. Kuo, et al. · Blood · 4

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial

2026 · Biree Andemariam, Kevin H M Kuo, et al. · The Lancet · 1

A Patient-Centric Approach to Sickle Cell Disease Clinical Trials: Integrating Patient Perspectives in the RISE UP Phase 2/3 Trial of Mitapivat for Informed Protocol Design and Associated Patient Community Benefit

2023 · Charles R. Jonassaint, Blaze Armon Eppinger, et al. · Blood · 1

A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study of Mitapivat in Patients With Sickle Cell Disease

2022 · KH Kuo, A Oluyadi, et al. · Hematology Transfusion and Cell Therapy

P107: a Phase 2/3, Randomized, Double-blind, Placebo-controlled Study of Mitapivat in Patients With Sickle Cell Disease

2022 · J Howard, K Kuo, et al. · HemaSphere

Works count: 11

Citation count: 127

H-index: 5

I10-index: 3